March 26, 2018
Cesca Therapeutics (KOOL) proposes RDO of 609,636 shares at $2.27 with warrants
February 7, 2018
Adverum Biotechnologies (ADVM) closed $69 M offering
January 22, 2018
Histogenics Corporation (HSGX) Prices Registered Direct Offering (RDO) of 2,340,430 shares at $2.35
January 22, 2018
Stemline Therapeutics (STML) proposes 3.7 M share offering
January 16, 2018
Intrexon (XON) Prices 6 M share offering at $12.50
January 12, 2018
AquaBounty Technologies (AQB) 3.69 M share, $12 M offering priced at $3.25
December 19, 2017
Northwest Bio (NWBO) Just another Ponzi financing scheme
December 14, 2017
Verastem (VSTM) proposes $25 M offering
December 13, 2017
Fate Therapeutics (FATE) closes $42.9 M offering at $4.20
December 12, 2017
bluebird bio (BLUE) Prices 3.343 M share offering at $185.00
December 11, 2017
VistaGen (VTGN) closes 10 M share offering at $1.50 with 100% warrant coverage
December 4, 2017
Northwest Biotherapeutics (NWBO) completed a $12 M financing
November 28, 2017
Cesca Therapeutics (KOOL) proposes 900 K share offering priced at $3.00
November 16, 2017
AxoGen (AXGN) Prices offering of 2 M share at $21.00
October 30, 2017
Pluristem (PSTI) proposes 8.87 M share offering with different pricing on Tel Aviv Stock exchange (TASE)
October 23, 2017
uniQure (QURE) proposes 5 M share offering
October 12, 2017
BioTime (NYSEMKT: BTX) proposes 9.515 M share offering
September 20, 2017
Juno Therapeutics (JUNO) proposes $225 M follow-on offering
August 31, 2017
VistaGen (VTGN) prices 1.37 M share offering at $1.75 with 1.89 M warrants attached
August 3, 2017
Spark Therapeutics (ONCE) Proposes 4.605 M share offering to raise $350 M
June 26, 2017
bluebird bio (BLUE) prices $350 M share offering at $105.00
June 20, 2017
Sangamo Therapeutics (SGMO) proposes $72.5 M offering
May 8, 2017
Capricor Therapeutics (CAPR) 1.96 M share offering priced at $3.10
April 10, 2017
Cytori (CYTX) 8.6 M share offering priced at $1.10 after stock jumps on BARDA news
April 1, 2017
Capricor Therapeutics (CAPR) at-the-market offering of $5 M
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors